Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≤2 cm in maximal dimension

Journal of Surgical Oncology

Volumn 110, Issue 2, 2014, Pages 99-106

  Lin, Mong Wei ^a,b   Wu, Chen Tu ^a,b   Shih, Jin Yuan ^a   Chang, Yih Leong ^a,b   Yang, Pan Chyr ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

epidermal growth factor receptor; lung adenocarcinoma; p53

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL DIFFERENTIATION; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE; TUMOR VOLUME;

EPIDERMAL GROWTH FACTOR RECEPTOR; LUNG ADENOCARCINOMA; P53;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ENZYME INHIBITORS; FEMALE; GENES, ERBB-1; GENES, P53; GENETIC MARKERS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PNEUMONECTOMY; PROGNOSIS; PROTEIN-TYROSINE KINASES; SURVIVAL ANALYSIS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84903940270     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23628     Document Type: Article

References (25)

1. Hoffman PC, Mauer AM, Vokes EE,: Lung cancer. Lancet 2000; 355: 479-485. (Pubitemid 30085163)
2. Yoshimi I, Ohshima A, Ajiki W, et al.: A comparison of trends in the incidence rate of lung cancer by histological type in the Osaka Cancer Registry, Japan and in the surveillance, epidemiology and end results program, USA. Jpn J Clin Oncol 2003; 33: 98-104. (Pubitemid 43115276)
3. Shigematsu H, Lin L, Takahashi T, et al.: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-346. (Pubitemid 40425952)
4. Olayioye MA, Neve RM, Lane HA, et al.: The ErbB signaling network: Receptor heterodimerization in development & cancer. EMBO J 2000; 19: 3159-3167. (Pubitemid 30428195)
5. Chang YL, Wu CT, Lin SC, et al.: Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers. Clin Cancer Res 2007; 13: 52-58.
6. Marks JL, Broderick S, Zhou Q, et al.: Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 2008; 3: 111-116. (Pubitemid 351323183)
7. Kobayashi N, Toyooka S, Ichimura K, et al.: Non-BAC component but not epidermal growth factor receptor gene mutation is associated with poor outcomes in small adenocarcinoma of the lung. J Thorac Oncol 2008; 3: 704-710.
8. Sugio K, Uramoto H, Ono K, et al.: Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 2006; 94: 896-903.
9. Mitsudomi T, Steinberg SM, Nau MM, et al.: p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992; 7: 171-180.
10. Finlay CA, Hinds PW, Levine AJ,: The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57: 1083-1093. (Pubitemid 19169804)
11. Kosaka T, Yatabe Y, Onozato R, et al.: Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 2009; 4: 22-29.
12. Mitsudomi T, Hamajima N, Ogawa M, et al.: Prognostic significance of p53 alterations in patients with non-small cell lung cancer: A meta-analysis. Clin Cancer Res 2000; 6: 4055-4063.
13. American Joint Committee on Cancer. Lung. In:, Edge S, Byrd DR, Compton CC, Fritz AG, Greene FI, Trotti A III, editors. AJCC Cancer Staging Manual, 7th edition. New York: Springer; 2010. pp. 253-270.
14. Linardou H, Dahabreh IJ, Kanaloupiti D, et al.: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systemic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9: 962-972.
15. Sidransky D, Mikkelsen T, Schwechheimer K, et al.: Clonal expansion of P53 mutant cells is associated with brain tumour progression. Nature 1992; 355: 846-847.
16. Travis WD, Brambilla E, Noguchi M, et al.: International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
17. Sobue T, Moriyama N, Kaneko M, et al.: Screening for lung cancer with low-dose helical computed tomography: Anti-lung cancer association project. J Clin Oncol 2002; 20: 911-920. (Pubitemid 34141832)
18. Lee YC, Chang YL, Luh SP, et al.: Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers. Ann Thorac Surg 1999; 68: 343-348.
19. Chang YL, Wu CT, Shih JY, et al.: Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers. Ann Surg Oncol 2011; 18: 543-550.
20. Chung KP, Huang YT, Chang YL, et al.: Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment. Chest 2012; 141: 420-428.
21. Chiba I, Takahashi T, Nau MM, et al.: Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene 1990; 5: 1603-1610.
22. Kawasaki M, Noguchi M, Morikawa A, et al.: Nuclear p53 accumulation by small-sized adenocarcinomas of the lung. Pathol Int 1996; 46: 486-490. (Pubitemid 26299465)
23. Chang YL, Wu CT, Shih JY, et al.: Roles of Fhit and p53 in Taiwanese surgically treated non-small-cell lung cancers. Br J Cancer 2003; 89: 320-326.
24. Harris CC,: p53 tumor suppressor gene: From the basic research laboratory to the clinic-an abridged historical perspective. Carcinogenesis 1996; 17: 1187-1198. (Pubitemid 26196329)
25. Chang YL, Lin MW, Shih JY, et al.: The significance of visceral pleural surface invasion in 321 cases of non-small cell lung cancers with pleural retraction. Ann Surg Oncol 2012; 19: 3057-3064.